5. Moderna

It is an mRNA-based vaccine, with the efficacy of 94.1%, the recommended age is 18 year and above.

Frozen, sterile, and preservative-free.
Multi-dose suspension.
One vial contains 10 doses of vaccine after thawing.
An interval of 28 days between doses is recommended.
The same product should be used for both doses.
Once thawed, vaccine is ready to use, do not dilute.
Before each vaccine withdrawal, swirl the vial gently, do not shake.
Inspect the vial to make sure that the liquid is white to off-white in color.
Do not use if any other particles or discoloration are present, in such cases discard the vial.
Use all vaccine within 6 hours after first puncture, do not combine residual vaccine from multiple vials.
Given intramuscularly, 0.5 ml, preferred site is deltoid muscle.

Thaw each vial before use.
Thaw vaccine at room temperature at 15 to 25 °C for 1 hour, or
Thaw vaccine in refrigerator at +2 to +8 °C for 2 hours and 30 minutes.
Let vial sit at room temperature for 15 minutes before vaccine administration.
After the first dose has been withdrawn, keep between 2 °C and 25 °C
Discard any unused vaccine after 6 hours, or at the end of the immunization session, whichever comes first.

Store in the original carton in a freezer at -25 to -15 °C.
Do not store on dry ice or below -40 °C.
Frozen unopened vaccine vial in freezer at -25 to -15 °C: from receipt until expiration date.
Thawed unopened vaccine vial in refrigerator at +2 to +8 °C up to 30 days.
Thawed unopened vaccine vial in cool storage up to room temperature from 8 °C to 25 °C up to 12 hours.
Thawed punctured vial at 2 to 25 °C up to 6 hours after the first dose has been withdrawn.
When thawed at 2 to 8 °C, keep at room temperature (up to 25 °C) for 15 minutes before use.
When thawed at room temperature (up to +25 °C) for 1 hour, vaccine can be used immediately.
The vaccine has no VVM, monitor the temperature at least twice per day.

Observed events are mostly mild to moderate and short lived.
Less frequent and severe in older (≥65 years) than in younger adults (18–64 years).
Generally, more frequent after the second dose compared to the first across all age groups.
Currently there have been increased reports of cases of inflammation of the heart called myocarditis and pericarditis.
Very common AEFIs: Headache, nausea, vomiting, myalgia and arthralgia.

A history of anaphylaxis to any component of the vaccine is a contraindication to vaccination.
mRNA-1273 vaccine should not be administered to individuals with a history of anaphylaxis to polyethylene glycol (PEG).
If anaphylaxis occurs after the first dose, a second dose of mRNA-1273 vaccine or of mRNA-BNT162b2 (Pfizer) should not be administered.